LCTX Stock Overview
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.
Lineage Cell Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.57|
|52 Week High||US$2.81|
|52 Week Low||US$1.10|
|1 Month Change||12.14%|
|3 Month Change||0%|
|1 Year Change||-42.91%|
|3 Year Change||41.44%|
|5 Year Change||-49.84%|
|Change since IPO||-54.05%|
Recent News & Updates
|LCTX||US Biotechs||US Market|
Return vs Industry: LCTX underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: LCTX underperformed the US Market which returned -21.2% over the past year.
|LCTX Average Weekly Movement||10.8%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: LCTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LCTX's weekly volatility (11%) has been stable over the past year.
About the Company
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.
Lineage Cell Therapeutics Fundamentals Summary
|LCTX fundamental statistics|
Is LCTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LCTX income statement (TTM)|
|Cost of Revenue||US$1.49m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.29|
|Net Profit Margin||-529.99%|
How did LCTX perform over the long term?See historical performance and comparison
Is LCTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LCTX?
Other financial metrics that can be useful for relative valuation.
|What is LCTX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does LCTX's PS Ratio compare to its peers?
|LCTX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
STRO Sutro Biopharma
ANIK Anika Therapeutics
AADI Aadi Bioscience
LCTX Lineage Cell Therapeutics
Price-To-Sales vs Peers: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the peer average (23.5x).
Price to Earnings Ratio vs Industry
How does LCTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is LCTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||29x|
|Fair PS Ratio||15.4x|
Price-To-Sales vs Fair Ratio: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the estimated Fair Price-To-Sales Ratio (15.4x).
Share Price vs Fair Value
What is the Fair Price of LCTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LCTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LCTX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LCTX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Lineage Cell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LCTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LCTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LCTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LCTX's revenue (52.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: LCTX's revenue (52.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LCTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Lineage Cell Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LCTX is currently unprofitable.
Growing Profit Margin: LCTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LCTX is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare LCTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LCTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: LCTX has a negative Return on Equity (-57.4%), as it is currently unprofitable.
Discover strong past performing companies
How is Lineage Cell Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LCTX's short term assets ($81.9M) exceed its short term liabilities ($24.6M).
Long Term Liabilities: LCTX's short term assets ($81.9M) exceed its long term liabilities ($34.7M).
Debt to Equity History and Analysis
Debt Level: LCTX is debt free.
Reducing Debt: LCTX has no debt compared to 5 years ago when its debt to equity ratio was 1.1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable LCTX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: LCTX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.5% per year.
Discover healthy companies
What is Lineage Cell Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LCTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LCTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LCTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LCTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LCTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Brian Culley (51 yo)
Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer at Lineage Cell Therapeutics, Inc. since January 20, 2021 until June 21, 2021. He serves as Chief Executive Officer at Artemis T...
CEO Compensation Analysis
Compensation vs Market: Brian's total compensation ($USD2.75M) is above average for companies of similar size in the US market ($USD1.83M).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
Experienced Management: LCTX's management team is considered experienced (3.3 years average tenure).
Experienced Board: LCTX's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.
Lineage Cell Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Lineage Cell Therapeutics, Inc.
- Ticker: LCTX
- Exchange: NYSEAM
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$266.472m
- Shares outstanding: 169.73m
- Website: https://www.lineagecell.com
Number of Employees
- Lineage Cell Therapeutics, Inc.
- 2173 Salk Avenue
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.